Skip to main content
Premium Trial:

Request an Annual Quote

Danaher Prices Public Offering at $51.75 per Share

The story has been updated to include the net proceed anount if underwriters exercise their over-allotment option in full.

By a GenomeWeb staff reporter

NEW YORK (GenomeWeb News) – Danaher late on Tuesday priced its public offering of 17.5 million shares of its common stock at $51.75 per share.

Net proceeds from the offering are expected to be at least $877.4 million and will be used to pay a portion of its pending $6.8 billion acquisition of Beckman Coulter. Proceeds also may be used for general corporate purposes, if there are any remaining from the offering or if the Beckman deal fails to chttps://www.genomeweb.com/archive/danaher-buying-beclose.

Underwriters on the offering have been granted a 30-day option to purchase up to an additional 1.75 million shares. In a document filed with the US Securities and Exchange Commission, Danaher said that if the underwriters exercise their over-allotment option in full, net proceeds will total around $965.3 million.

Citi, Morgan Stanley & Co., Barclays Capital, and UBS Securities are joint book-running managers for the offering. Baird, Jefferies & Co., Banca IMI, Mitsubishi UFJ Securities, and Wells Fargo Securities are acting as co-managers.

The offering is expected to close on June 21.

The Scan

Renewed Gain-of-Function Worries

The New York Times writes that the pandemic is renewing concerns about gain-of-function research.

Who's Getting the Patents?

A trio of researchers has analyzed gender trends in biomedical patents issued between 1976 and 2010 in the US, New Scientist reports.

Other Uses

CBS Sunday Morning looks at how mRNA vaccine technology could be applied beyond SARS-CoV-2.

PLOS Papers Present Analysis of Cervicovaginal Microbiome, Glycosylation in Model Archaea, More

In PLOS this week: functional potential of the cervicovaginal microbiome, glycosylation patterns in model archaea, and more.